New in-licensing opportunities in inflammation Challenge A small molecule pharmaceutical incubator is using a novel and proprietary drug discovery and translational platform to develop first-in-class, small molecule therapeutics for the treatment of inflammatory diseases. The incubator’s novel approach to drug discovery is based on the identification of genomic targets from tissue analysis of inflammatory disease patients, which allows for the development of therapies targeting the hallmarks of the disease. The company had recently taken the strategic decision to supplement its internal product generation engine with external innovation, and therefore engaged Alacrita to scout for in-licensing opportunities with a focus on early preclinical or clinical stage assets; inflammatory bowel dise

Join for free to read